On October 12, 2026, Bristol Myers Squibb (BMS) announced that it had achieved primary endpoints in two Phase 3 trials. One ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results